Could you please clarify the mortality rate associated with Extracorporeal Membrane Oxygenation (ECMO) therapy? I'm interested in understanding the risk factor and how it may vary depending on the patient's condition and the reasons for undergoing this treatment. Also, are there any recent studies or data that provide insights into the survival rates of patients who have undergone ECMO?
            
            
            
            
            
            
           
          
          
            7 answers
            
            
  
    
    Martino
    Sun Oct 06 2024
   
  
    The mortality rates in patients with Acute Respiratory Distress Syndrome (ARDS) undergoing Extracorporeal Membrane Oxygenation (ECMO) therapy exhibit a wide range, varying from 22% to 62.6%. This variability underscores the complexity of the treatment and the need for careful consideration of multiple factors.
  
  
 
            
            
  
    
    SsamziegangSerenadeMelodyHarmonySoul
    Sun Oct 06 2024
   
  
    Researchers have identified several potential predictors of mortality in ARDS patients undergoing ECMO therapy. These factors, when analyzed and understood, can aid in predicting patient outcomes and inform clinical decision-making.
  
  
 
            
            
  
    
    Giuseppe
    Sun Oct 06 2024
   
  
    One such factor is the severity of the patient's underlying condition prior to ECMO initiation. Patients with more severe ARDS and associated comorbidities are often at higher risk of mortality.
  
  
 
            
            
  
    
    Sebastiano
    Sat Oct 05 2024
   
  
    The duration of ECMO support is also a critical factor. Prolonged ECMO therapy can lead to complications such as bleeding, infections, and organ dysfunction, all of which can contribute to increased mortality.
  
  
 
            
            
  
    
    Chiara
    Sat Oct 05 2024
   
  
    The patient's age and overall health status also play a role in predicting mortality. Older patients and those with pre-existing conditions may have a harder time recovering from ARDS and ECMO therapy.